Do bisphosphonates have a role in the management of foot lameness?
Author(s):
Updated:
SEP 15, 2018
Languages:
Read
Bisphosphonates (BPs) were first created in the 1960s; they are thought to be the most potent inhibitor of bone resorption and, therefore, are used in the treatment of people with Paget’s disease, osteoporosis and osteolytic bone metastasis [1,2]. They reduce bone resorption by causing osteoclastic apoptosis, either via accumulation of cytotoxic ATP (non-nitrogen-containing or ‘simple’ BPs like etidronate, clodronate, tiludronate) or via altering the mevalonate pathway (nitrogen-containing BPs like alendronate, pamidronate, zoledronate) [3,4] ...
About
How to reference this publication (Harvard system)?
(2020) “Do bisphosphonates have a role in the management of foot lameness?”, BEVA - Annual Congress - Birmingham, 2018. Available at: https://www.ivis.org/library/beva/beva-annual-congress-birmingham-2018/do-bisphosphonates-have-a-role-management-of-foot-lameness (Accessed: 12 September 2024).
Affiliation of the authors at the time of publication
Tierklinik Lüsche, Essener Strasse 39, D-49456 Bakum, Germany.
Author(s)
Copyright Statement
© All text and images in this publication are copyright protected and cannot be reproduced or copied in any way.Provided by:
Comments (0)
Ask the author
0 comments